ONCOLOGY - INJECTABLE

E-SCRIBE and FAX ENROLLMENT FORM

☐ **NOBLE NORTHEAST:** E-Scribe: **NOBLE** | Fax: **888-842-3977** | Tel: 888-843-2040

☐ **NOBLE SOUTHEAST:** E-Scribe: **NOBLEMS/TRANSCRIPT** | Fax: **601-420-4040** | Tel: 866-420-4041

Delivery Needed By: ____________ Deliver to: ☐ Patient's Home ☐ Physician's Office ☐ Other: __________

PATIENT INFORMATION	PROVIDER INFORMATION
Patient Name: ____________ ☐ Male	Prescriber's Name: ____________
Street Address: ____________ ☐ Female	Office Contact Name: ____________
City: ________ State: ____ Zip Code: ______	Address: ____________
Phone Number: ____________	City: ________ State: ____ Zip Code: ______
Email Address: ____________	Phone Number: ________ Fax Number: ________
Last Four of Social: ________ Date of Birth: ________	DEA/NPI #: ____________

INSURANCE - PLEASE FAX A COPY OF PRESCRIPTION CARD FRONT & BACK

CLINICAL INFORMATION

Diagnosis: ____________

Has the patient been treated previously for this condition?

ICD-10 Code: ____________

☐ Yes ☐ No

Height: ______ft ______ ins Weight: ______ lbs

Medications Failed: ____________

Allergies: ____________

Medications On: ____________

Other Notes: ____________

PRESCRIPTION INFORMATION

Medication:	Dosage/Strength:	Directions:	Quantity:	Refills:
Abraxane	☐ 100mg vial	☐ 100mg/m² (____ mg) IV over 30 minutes on days 1, 8, 15 of each 21 day cycle ☐ 125mg/m² (____ mg) IV over 30-40 minutes on days 1, 8, 15 of each 28 day cycle ☐ 260mg/m² (____ mg) IV over 30 minutes every 3 weeks ☐ Other	☐ ______ vials	
Adrucil® fluorouracil	☐ 50mg/ml vial		☐ ______ vials	
Arzerra®	☐ 100mg/5ml vial ☐ 1000mg/50ml vial	☐ 300mg IV on Day 1 followed by 1000mg on Day 8 (CYCLE 1); 1000mg on Day 1 of subsequent 28 day cycles ☐ 1000mg IV every 8 weeks ☐ 300mg IV on Day 1 followed by 2000mg weekly starting 1 week after initial dose ☐ 2000mg IV every 4 weeks	☐ ______ vials	
Avastin®	☐ 100mg/4ml (25mg/ml) vial ☐ 400mg/16ml (25mg/ml) vial	☐ _____mg/kg IV every _____ weeksh	☐ ______ vials	
Belrapzo™	☐ 100 mg/4ml (25mg/ml) vial	☐ 100mg/m² (____ mg) IV over 30 minutes on days 1 and 2 of 28 day cycle ☐ 120mg/m² (____ mg) IV over 60 minutes on days 1 and 2 of a 21 day cycle	☐ ______ vials	
Bendeka	☐ 25mg/ml	☐ 100mg/m² (____ mg) IV over 10 minutes on days 1 and 2 of 28 day cycle ☐ 120mg/m² (____ mg) IV over 10 minutes on days 1 and 2 of a 21 day cycle	☐ ______ vials	
Cisplatin®	☐ 50mg vial ☐ 1mg/ml IV solution	☐ _____mg/m² (_____mg) IV ___________	☐ ______ vials	
Cyclophosphamide	☐ 500 mg vial ☐ 1g vial ☐ 2g vial		☐ ______ vials	

☐ Patient is interested in patient support programs ☐ Ancillary supplies provided for administration

Physician Signature: ____________________ Date: ____________________

NATIONALLY ACCREDITED. **100% EMPLOYEE OWNED.**
www.noblehealthservices.com

Important Notice: This communication contains information that is confidential and protected from disclosure. If the reader of this message is not the intended recipient, employee or agent responsible for delivering the message to the intended recipient, you are hereby notified that any dissemination, distribution, or copying of this communication is strictly prohibited. If you have received this communication in error, please reply to the sender that you have received the message in error and destroy this copy. V. Q420201

ONCOLOGY - INJECTABLE

E-SCRIBE and FAX ENROLLMENT FORM

☐ **NOBLE NORTHEAST:** E-Scribe: **NOBLE** | Fax: **888-842-3977** | Tel: 888-843-2040

☐ **NOBLE SOUTHEAST:** E-Scribe: **NOBLEMS/TRANSCRIPT** | Fax: **601-420-4040** | Tel: 866-420-4041

Delivery Needed By: ____________ Deliver to: ☐ Patient's Home ☐ Physician's Office ☐ Other: ________

PATIENT INFORMATION	PROVIDER INFORMATION
Patient Name: ______________ ☐ Male	Prescriber's Name: ______________
Street Address: ______________ ☐ Female	Office Contact Name: ______________
City: ________ State: ____ Zip Code: ______	Address: ______________
Phone Number: ______________	City: ________ State: ____ Zip Code: ____
Email Address: ______________	Phone Number: ________ Fax Number: ________
Last Four of Social: ________ Date of Birth: ________	DEA/NPI #: ______________

INSURANCE - PLEASE FAX A COPY OF PRESCRIPTION CARD FRONT & BACK

CLINICAL INFORMATION

Diagnosis: ______________

Has the patient been treated previously for this condition?

☐ Yes ☐ No

ICD-10 Code: ______________

Height: ______ ft ______ ins Weight: ______ lbs

Medications Failed: ______________

Allergies: ______________

Medications On: ______________

Other Notes: ______________

PRESCRIPTION INFORMATION

Medication:	Dosage/Strength:	Directions:	Quantity:	Refills:
Dacogen decitabine	☐ 50mg vial	☐ 15 mg/m² (____mg) IV over 3 hours repeated every 8 hours for 3 days; repeat cycle every 6 weeks ☐ 20mg/m² (____mg) IV over 1 hour repeated daily for 5 days; repeat cycle every 4 weeks ☐ Other	☐ ______ vials	
Darzalex®	☐ 400mg/20ml vial ☐ 100mg/5ml vial	☐ 16mg/kg (____mg) IV______________	☐ ______ vials	
Empliciti®	☐ 300mg vial ☐ 400mg vial	☐ 10mg/kg (_____mg) IV once every week for first 2 cycles ☐ 10mg/kg (____mg) IV every 2 weeks ☐ 20mg/kg (____mg) IV every 4 weeks ☐ Other	☐ ______ vials	
Erbitux®	☐ 100mg/50ml vial ☐ 200mg/100ml vial	Loading dose: ☐ 400 mg/m² (____mg) IV over 120 minutes day 1 Weekly doses: ☐ 250 mg/m² (____mg) IV over 60 minutes weekly starting day 8	☐ ______ vials	
Etopophos	☐ 100mg vial		☐ ______ vials	
Evomela	☐ 50mg vial	☐ 100mg/m²/day (___ mg) IV over 30 minutes for 2 consecutive days ☐ 16mg/m² (___ mg) IV over 15 to 20 minutes at 2-week intervals for 4 doses, then at 4 week intervals	☐ ______ vials	
fluorouracil	☐ 50mg/ml vial		☐ ______ vials	
Folotyn	☐ 20mg/1ml vial ☐ 40mg/2ml vial	☐ 30mg/m² (____mg) IV push over 3-5 minutes once weekly x6weeks in 7-week cycles	☐ ______ vials	
Fusilev®	☐ 50mg vial	☐ 10mg/m² (____mg) IV daily for 5 days ☐ 100mg/m²(____ mg) slow IV push over a minimum of 3 minutes daily for 5 days	☐ ______ vials	

☐ Patient is interested in patient support programs ☐ Ancillary supplies provided for administration

Physician Signature: ______________________ Date: ______________________

NATIONALLY ACCREDITED. **100% EMPLOYEE OWNED.**

www.noblehealthservices.com

Important Notice: This communication contains information that is confidential and protected from disclosure. If the reader of this message is not the intended recipient, employee or agent responsible for delivering the message to the intended recipient, you are hereby notified that any dissemination, distribution, or copying of this communication is strictly prohibited. If you have received this communication in error, please reply to the sender that you have received the message in error and destroy this copy. V. Q420201

ONCOLOGY - INJECTABLE
E-SCRIBE and FAX ENROLLMENT FORM

☐ **NOBLE NORTHEAST:** E-Scribe: **NOBLE** | Fax: **888-842-3977** | Tel: 888-843-2040
☐ **NOBLE SOUTHEAST:** E-Scribe: **NOBLEMS/TRANSCRIPT** | Fax: **601-420-4040** | Tel: 866-420-4041

Delivery Needed By: ____________ Deliver to: ☐ Patient's Home ☐ Physician's Office ☐ Other: __________

PATIENT INFORMATION	PROVIDER INFORMATION
Patient Name: ____________ ☐ Male	Prescriber's Name: ____________
Street Address: ____________ ☐ Female	Office Contact Name: ____________
City: ________ State: ____ Zip Code: ________	Address: ____________
Phone Number: ____________	City: ________ State: ____ Zip Code: _____
Email Address: ____________	Phone Number: ________ Fax Number: ________
Last Four of Social: ________ Date of Birth: ________	DEA/NPI #: ____________

INSURANCE - PLEASE FAX A COPY OF PRESCRIPTION CARD FRONT & BACK

CLINICAL INFORMATION

Diagnosis: ____________

Has the patient been treated previously for this condition?

☐ Yes ☐ No

ICD-10 Code: ____________

Height: ________ft ________ ins Weight: ________ lbs

Medications Failed: ____________

Allergies: ____________

Medications On: ____________

Other Notes: ____________

PRESCRIPTION INFORMATION

Medication:	Dosage/Strength:	Directions:	Quantity:	Refills:
Granix® tbo-filgrastim	☐ 300mcg/0.5ml prefilled syringe ☐ 480mcg/0.8 ml prefilled syringe ☐ 300mcg/ml vial ☐ 480mcg/1.6ml vial	☐ Inject 5mcg/kg/day (_____mcg) SC once daily for ______ days ☐ Other	☐ ______ doses	
Halaven®	☐ 1mg/2ml vial	☐ 1.4mg/m² (____mg) IV over 2-5 minutes on Day 1 and 8 of 21-day cycle ☐ Other	☐ ______ vials	
Herceptin®	☐ 150mg vial ☐ 420mg vial		☐ ______ vials	
Hycamtin®	☐ 4mg vial	☐ 1.5mg/m² (___ mg) IV over 30 minutes daily x5 consecutive days starting on day 1 of a 21 day cycle ☐ 0.75mg/m² (____mg) over 30 minutes on Days 1, 2, 3 of a 21-day cycle ☐ Other	☐ ______ vials	
Imlygic	☐ 1,000,000 PFU/mL vial ☐ 100,000,000 PFU/mL vial	☐ Inject each cutaneous, subcutaneous, and/or nodal lesion with ____ ml	☐ ______ vials	
Intron® A	☐ 10 million unit powder for injection ☐ 18 million unit powder for injection ☐ 50 million unit powder for injection ☐ 18 million unit solution for injection ☐ 25 million unit solution for injection		☐ ______ vials	
Ixempra	☐ 15mg vial ☐ 45mg vial	☐ 40mg/m² (___mg) IV over 3 hours every 3 weeks ☐ Other		
Jevtana®	☐ 60mg/1.5 mL vial	☐ 20mg/m² (__ mg) IV over 1 hour every 3 weeks ☐ 25mg/m² (___mg) IV over 1 hour every 3 weeks ☐ Other		

☐ Patient is interested in patient support programs ☐ Ancillary supplies provided for administration

Physician Signature: ____________________ Date: ____________________

NATIONALLY ACCREDITED. **100% EMPLOYEE OWNED.**
www.noblehealthservices.com

Important Notice: This communication contains information that is confidential and protected from disclosure. If the reader of this message is not the intended recipient, employee or agent responsible for delivering the message to the intended recipient, you are hereby notified that any dissemination, distribution, or copying of this communication is strictly prohibited. If you have received this communication in error, please reply to the sender that you have received the message in error and destroy this copy. V. Q420201

ONCOLOGY - INJECTABLE

E-SCRIBE and FAX ENROLLMENT FORM

☐ **NOBLE NORTHEAST:** E-Scribe: **NOBLE** | Fax: **888-842-3977** | Tel: 888-843-2040

☐ **NOBLE SOUTHEAST:** E-Scribe: **NOBLEMS/TRANSCRIPT** | Fax: **601-420-4040** | Tel: 866-420-4041

Delivery Needed By: ____________ Deliver to: ☐ Patient's Home ☐ Physician's Office ☐ Other: ________

PATIENT INFORMATION	PROVIDER INFORMATION
Patient Name: ______________ ☐ Male	Prescriber's Name: ______________
Street Address: ______________ ☐ Female	Office Contact Name: ______________
City: ________ State: ____ Zip Code: ______	Address: ______________
Phone Number: ______________	City: ________ State: ____ Zip Code: ____
Email Address: ______________	Phone Number: ________ Fax Number: ________
Last Four of Social: ________ Date of Birth: ________	DEA/NPI #: ______________

INSURANCE - PLEASE FAX A COPY OF PRESCRIPTION CARD FRONT & BACK

CLINICAL INFORMATION

Diagnosis: ______________

Has the patient been treated previously for this condition?

☐ Yes ☐ No

ICD-10 Code: ______________

Height: ________ ft ________ ins Weight: ________ lbs

Medications Failed: ______________

Allergies: ______________

Medications On: ______________

Other Notes: ______________

PRESCRIPTION INFORMATION

Medication:	Dosage/Strength:	Directions:	Quantity:	Refills:
Keytruda®	☐ 50mg powder for injection ☐ 100mg/4mL solution in vial	☐ 200mg IV infusion over 30 minutes every 3 weeks ☐ Other	☐ ______ vials	
Levoleucovorin	☐ 175mg /17.5ml vial ☐ 250mg / 25ml vial ☐ 50mg powder for injection ☐ 175mg powder for injection ☐ 300mg powder for injection	Routes: ☐ IV ☐ IV infusion ☐ IV injection ☐ Administer __ mg IV infusion every _____ ☐ Other	☐ ______ vials	
Marqibo®	☐ 5mg/31ml vial	☐ 2.25mg/m² (___mg) IV over 1 hour every 7 days ☐ Other	☐ ______ vials	
Mozobil	☐ 24mg/1.2ml vial	☐ ____mg SC once daily for 4 days ☐ Other	☐ ______ vials	
Neulasta® pegfilgrastim	☐ 6mg/0.6ml prefilled syringe ☐ 6mg/0.6ml Onpro Kit	☐ Inject 6mg SC once per chemotherapy cycle ☐ Other	☐ _____ prefilled syringes ☐ _____ Onpro kits	
Neupogen® filgrastim	Prefilled Syringe: ☐ 300mcg/0.5ml syringe ☐ 480mcg/0.8ml syringe Vial: ☐ 300mcg/ml vial ☐ 480mcg/1.6ml vial	☐ Administer___ mcg IV once a day for ____ days ☐ Administer ___ mcg SC once a day for ____ days ☐ Other	☐ ______ vials ☐ ______ prefilled syringes	
Novantrone Mitoxantrone	☐ 20mg/10mL vial ☐ 25mg/12.5mL ☐ 30mg/15mL vial	☐ 12mg/m²/day (_____mg) IV on days 1-3 ☐ Other		

☐ Patient is interested in patient support programs ☐ Ancillary supplies provided for administration

Physician Signature: ______________ Date: ______________

NATIONALLY ACCREDITED. **100% EMPLOYEE OWNED.**

www.noblehealthservices.com

Important Notice: This communication contains information that is confidential and protected from disclosure. If the reader of this message is not the intended recipient, employee or agent responsible for delivering the message to the intended recipient, you are hereby notified that any dissemination, distribution, or copying of this communication is strictly prohibited. If you have received this communication in error, please reply to the sender that you have received the message in error and destroy this copy. V. Q420201

ONCOLOGY - INJECTABLE

E-SCRIBE and FAX ENROLLMENT FORM

☐ **NOBLE NORTHEAST:** E-Scribe: **NOBLE** | Fax: **888-842-3977** | Tel: 888-843-2040
☐ **NOBLE SOUTHEAST:** E-Scribe: **NOBLEMS/TRANSCRIPT** | Fax: **601-420-4040** | Tel: 866-420-4041

Delivery Needed By: ____________ Deliver to: ☐ Patient's Home ☐ Physician's Office ☐ Other: __________

PATIENT INFORMATION	PROVIDER INFORMATION
Patient Name: ______________ ☐ Male	Prescriber's Name: ______________
Street Address: ______________ ☐ Female	Office Contact Name: ______________
City: __________ State: _____ Zip Code: ______	Address: ______________
Phone Number: ______________	City: __________ State: _____ Zip Code: ______
Email Address: ______________	Phone Number: ________ Fax Number: ________
Last Four of Social: ________ Date of Birth: ________	DEA/NPI #: ______________

INSURANCE - PLEASE FAX A COPY OF PRESCRIPTION CARD FRONT & BACK

CLINICAL INFORMATION

Diagnosis: ______________

Has the patient been treated previously for this condition?

☐ Yes ☐ No

ICD-10 Code: ______________

Height: ________ft ________ ins Weight: ________ lbs

Medications Failed: ______________

Allergies: ______________

Medications On: ______________

Other Notes: ______________

PRESCRIPTION INFORMATION

Medication:	Dosage/Strength:	Directions:	Quantity:	Refills:
Nplate®	☐ 125mcg vial ☐ 250mcg vial ☐ 500mcg vial	☐ 1mcg/kg (____mcg) SC once weekly ☐ Other	☐ ______ vials	
Opdivo®	☐ 40mg vial ☐ 100mg vial ☐ 240mg vial	☐ 240mg IV infusion over 30 minutes every 2 weeks ☐ 480mg IV infusion over 30 minutes every 4 weeks ☐ Other	☐ ______ vials	
Polivy™	☐ 140mg lyophilized powder in a single-dose vial	☐ 1.8mg/kg (____mg) IV infusion over 30-90 minutes every 21 days for 6 cycles ☐ Other	☐ ______ vials	
Proleukin®	☐ 22,000,000 unit vial- powder for injection	☐ Give 600,000 IU/kg (______IU) IV every 8 hours for 14 doses, repeat after 9 day rest period ☐ Other	☐ ______ vials	
Rituxan®	☐ 100mg/10ml vial ☐ 500mg/50ml vial		☐ ______ vials	
Soliris®	☐ 300mg/30mL vial	☐ 600mg IV infusion once weekly for 4 weeks ☐ 900mg IV infusion for 5th dose ☐ 900mg IV infusion every 2 weeks ☐ Other	☐ ______ vials	
Sylvant™	☐ 100mg vial ☐ 400mg vial	☐ 11mg/kg (____mg) IV over 1 hour every 3 weeks ☐ Other	☐ ______ vials	
Thyrogen®	☐ 1.1mg vial	☐ Inject 0.9mg IM every 24 hours for 2 doses	☐ ______ vials	
Topotecan	☐ 4mg vial- powder for injection ☐ 4mg/4mL vial- solution for injection		☐ ______ vials	
Torisel®	☐ 25mg/ml	☐ 25mg IV infusion over 30-60 minutes once weekly ☐ Other	☐ ______ vials	

☐ Patient is interested in patient support programs ☐ Ancillary supplies provided for administration

Physician Signature: ______________________ Date: ______________________

NATIONALLY ACCREDITED. **100% EMPLOYEE OWNED.**
www.noblehealthservices.com

Important Notice: This communication contains information that is confidential and protected from disclosure. If the reader of this message is not the intended recipient, employee or agent responsible for delivering the message to the intended recipient, you are hereby notified that any dissemination, distribution, or copying of this communication is strictly prohibited. If you have received this communication in error, please reply to the sender that you have received the message in error and destroy this copy. V. Q420201

ONCOLOGY - INJECTABLE

E-SCRIBE and FAX ENROLLMENT FORM

☐ **NOBLE NORTHEAST:** E-Scribe: **NOBLE** | Fax: **888-842-3977** | Tel: 888-843-2040

☐ **NOBLE SOUTHEAST:** E-Scribe: **NOBLEMS/TRANSCRIPT** | Fax: **601-420-4040** | Tel: 866-420-4041

Delivery Needed By: ____________ Deliver to: ☐ Patient's Home ☐ Physician's Office ☐ Other: __________

PATIENT INFORMATION	PROVIDER INFORMATION
Patient Name: ____________ ☐ Male	Prescriber's Name: ____________
Street Address: ____________ ☐ Female	Office Contact Name: ____________
City: ________ State: ____ Zip Code: ________	Address: ____________
Phone Number: ____________	City: ________ State: ____ Zip Code: ____
Email Address: ____________	Phone Number: ________ Fax Number: ________
Last Four of Social: ________ Date of Birth: ________	DEA/NPI #: ____________

INSURANCE - PLEASE FAX A COPY OF PRESCRIPTION CARD FRONT & BACK

CLINICAL INFORMATION

Diagnosis: ____________

Has the patient been treated previously for this condition?

ICD-10 Code: ____________ ☐ Yes ☐ No

Height: ________ ft ________ ins Weight: ________ lbs

Medications Failed: ____________

Allergies: ____________

Medications On: ____________

Other Notes: ____________

PRESCRIPTION INFORMATION

Medication:	Dosage/Strength:	Directions:	Quantity:	Refills:
Treanda®	☐ 25mg powder for injection ☐ 100mg powder for injection ☐ 45mg/0.5ml solution for injection ☐ 180mg/2ml solution for injection	☐ 100mg/m² (__ mg) IV over 30 minutes on days 1 and 2 ; repeat every 28 days for up to 6 cycles ☐ 120mg/m² (__ mg) IV over 60 minutes on days 1 and 2 of a 21-day cycle for up to 8 cycles ☐ Other	☐ ______ vials	
Valstar®	☐ 200mg/5mL vial	☐ 800mg intravesically once weekly for 6 weeks; solution should be retained for 2 hours (when possible) prior to voiding ☐ Other	☐ ______ vials	
Vectibix®	☐ 100mg/5ml vial ☐ 400mg/20ml vial	☐ 6mg/kg (____mg) IV infusion over 60 minutes (dose </=1000mg) ☐ 6mg/kg (____mg) IV infusion over 90 minutes (dose >1000mg) ☐ Other	☐ ______ vials	
Velcade®	☐ 3.5mg vial-powder for injection		☐ ______ vials	
Vidaza® azacitidine	☐ 100mg vial	☐ 75mg/m² (____ mg) IV daily for 7 days; repeat cycle every 4 weeks ☐ 100mg/m² (____ mg) IV daily for 7 days; repeat cycle every 4 weeks ☐ 75mg/m² (____ mg) SC daily for 7 days; repeat cycle every 4 weeks ☐ 100mg/m² (____ mg) SC daily for 7 days; repeat cycle every 4 weeks ☐ Other	☐ ______ vials	

☐ Patient is interested in patient support programs ☐ Ancillary supplies provided for administration

Physician Signature: ____________________ Date: ____________________

NATIONALLY ACCREDITED. **100% EMPLOYEE OWNED.**

www.noblehealthservices.com

Important Notice: This communication contains information that is confidential and protected from disclosure. If the reader of this message is not the intended recipient, employee or agent responsible for delivering the message to the intended recipient, you are hereby notified that any dissemination, distribution, or copying of this communication is strictly prohibited. If you have received this communication in error, please reply to the sender that you have received the message in error and destroy this copy. V. Q420201

ONCOLOGY - INJECTABLE

E-SCRIBE and FAX ENROLLMENT FORM

☐ **NOBLE NORTHEAST:** E-Scribe: **NOBLE** | Fax: **888-842-3977** | Tel: 888-843-2040

☐ **NOBLE SOUTHEAST:** E-Scribe: **NOBLEMS/TRANSCRIPT** | Fax: **601-420-4040** | Tel: 866-420-4041

Delivery Needed By: ____________ Deliver to: ☐ Patient's Home ☐ Physician's Office ☐ Other: ________

PATIENT INFORMATION	PROVIDER INFORMATION
Patient Name: ______________ ☐ Male	Prescriber's Name: ______________
Street Address: ______________ ☐ Female	Office Contact Name: ______________
City: ________ State: ____ Zip Code: ______	Address: ______________
Phone Number: ______________	City: ________ State: ____ Zip Code: ____
Email Address: ______________	Phone Number: ________ Fax Number: ________
Last Four of Social: ________ Date of Birth: ________	DEA/NPI #: ______________

INSURANCE - PLEASE FAX A COPY OF PRESCRIPTION CARD FRONT & BACK

CLINICAL INFORMATION

Diagnosis: ______________

Has the patient been treated previously for this condition?

ICD-10 Code: ______________

☐ Yes ☐ No

Height: ______ft ________ ins Weight: ______ lbs

Medications Failed: ______________

Allergies: ______________

Medications On: ______________

Other Notes: ______________

PRESCRIPTION INFORMATION

Medication:	Dosage/Strength:	Directions:	Quantity:	Refills:
Xgeva®	☐ 120mg/1.7ml single dose vial	☐ 120mg SC every 4 weeks ☐ 120mg SC every 4 weeks with additional 120mg dose on days 8, 15 of first month therapy ☐ Other	☐ ______ vials	
Yervoy®	☐ 50mg/10ml vial ☐ 200mg/40ml vial	☐ 50mg/10ml vial ☐ 200mg/40ml vial	☐ ______ vials	
Yondelis®	☐ 1mg vial- powder for injection	☐ 1.5mg/m² (___mg) 24 hour IV infusion (through central line) every 3 weeks ☐ Other	☐ ______ vials	
Zaltrap®	☐ 100mg/4 mL vial ☐ 200mg/8 mL vial	☐ 4mg/kg (___mg) IV infusion over 1 hour every 2 weeks	☐ ______ vials	
Zarxio® filgrastim- sndz	☐ 300mcg/0.5ml syringe ☐ 480mcg/0.8ml syringe	☐ Administer___ mcg IV once a day for ____ days ☐ Administer ___ mcg SC once a day for ____ days ☐ Other	☐ ______ prefilled syringes	
Zometa® zoledronic acid	☐ 4mg vial- powder for injection ☐ 4mg/100ml- solution for injection ☐ 4mg/5ml solution for injection	☐ 4mg IV infused over at least 15 minutes for _____ dose(s) ☐ 4mg IV infused over at least 15 minutes once every 3-4 weeks ☐ Other	☐ ______ vials	
Other				

☐ Patient is interested in patient support programs ☐ Ancillary supplies provided for administration

Physician Signature: ______________________ Date: ______________________

NATIONALLY ACCREDITED. **100% EMPLOYEE OWNED.**

www.noblehealthservices.com

Important Notice: This communication contains information that is confidential and protected from disclosure. If the reader of this message is not the intended recipient, employee or agent responsible for delivering the message to the intended recipient, you are hereby notified that any dissemination, distribution, or copying of this communication is strictly prohibited. If you have received this communication in error, please reply to the sender that you have received the message in error and destroy this copy. V. Q420201